Seqens commits to US market with multi-million dollar investment in R&D

A redeveloped R&D facility will enhance Seqens' capabilities in developing and producing APIs and active delivery systems development

The investment will enable the specialist manufacturer of APIs and pharmaceutical intermediates to increase its R&D capability and productivity of APIs and active delivery systems (lipids and polymers) development which, in turn, will bolster its global R&D network. 

Furthermore, the transaction is set to strengthen the company’s US foothold — which also includes a sales office and CDMO operation in nearby Newburyport — and demonstrates the company's commitment to broadening its reach in the US market. 

In addition to the re-development of its Devens laboratory, Seqens is investing significantly across the enterprise in its commercial and development products and technology platforms, including custom polymers, lipids, flow chemistry, HPAPIs and biocatalysts. 

Seqens' President Pierre Luzeau said the combination of Wavelength's technologies, products and expertise will enable the company to "accelerate the projects launched in recent months" and support customers worldwide in the development of their projects. 

The merger with Wavelength broadens Seqens' global reach by providing production facilities in Israel and India, and sales offices in Europe and the US.  

The expansion projection is expected to be completed by the beginning of 2023.